The Numbers Are Real and They're Impressive

Moderna and Merck announced five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study on January 20, 2026. The headline result: the combination of intismeran autogene and Keytruda reduced the risk of recurrence or death by 49% compared to Keytruda alone.

That's a hazard ratio of 0.510 with a 95% confidence interval of 0.294–0.887. The numbers indicate the result is statistically significant.

According to NPR's reporting citing Dr. Janice Mehnert — melanoma specialist and senior author of the new paper published in the Journal of Clinical Oncology — 68.8% of patients receiving the combination therapy were cancer-free at five years, versus 49.1% in the Keytruda-only group. The survival gap is even starker: 92% alive at five years in the combo group, compared to 71% in the Keytruda-only group.

The survival difference amounts to 21 percentage points. This is a meaningful clinical outcome.

What This Vaccine Actually Is

This isn't a mass-produced shot. It's a personalized therapy built from your own tumor.

After surgery removes the melanoma, scientists sequence the tumor's DNA to identify unique mutations specific to that patient. The mRNA vaccine is then custom-manufactured to train the immune system to hunt down any remaining cancer cells carrying those mutations.

According to a peer-reviewed paper published in Cells in September 2025 by researchers Stefano Zoroddu and Luigi Bagella at the University of Sassari, melanoma is an ideal candidate for this approach because it carries one of the highest mutational burdens of any cancer — meaning there are more tumor-specific targets for the immune system to recognize and attack.

The vaccine is delivered via lipid nanoparticles — the same delivery mechanism used in Moderna's COVID-19 vaccine. The mRNA itself never enters the cell nucleus and does NOT alter DNA.

The Trial: Small but Structured

The study involved 157 patients across Australia and the United States — all of whom had surgery to remove high-risk Stage III or Stage IV melanoma tumors. This is a Phase 2b trial, not a Phase 3. That distinction matters.

Phase 2b means promising results in a controlled setting with a moderate patient population. It does NOT mean FDA approval is imminent. According to Merck's own announcement, Moderna and Merck have eight Phase 2 and Phase 3 trials underway across multiple tumor types including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

The Phase 3 adjuvant melanoma trial — the one that would actually drive a regulatory decision — is still in progress. Media coverage hyping this as a near-term available treatment is getting ahead of the data.

Political Collision in Washington

NPR covered this competently on the science. What received less attention is the direct policy collision happening in Washington right now.

NPR's own reporting notes that public health experts are "dismayed" by RFK Jr.'s defunding of mRNA vaccine research. The Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., has moved to cut funding streams that support exactly this kind of mRNA platform research.

The tension is significant: the same technology being used to fight cancer is politically radioactive because of COVID-19 vaccine controversies. The mRNA platform doesn't know or care about politics. It encodes proteins. Using COVID vaccine skepticism as justification to defund cancer research carries real consequences for patients.

Legitimate concerns about COVID vaccine mandates, government overreach, and pharmaceutical accountability are separate from the question of whether to eliminate a research platform that reduces cancer deaths by 21 percentage points over five years.

Defunding this research pipeline amounts to cutting off a treatment that works based on political grievance.

The Cost and Access Problem

Personalized vaccines aren't cheap. Each one is manufactured specifically for a single patient based on their individual tumor sequencing. The manufacturing pipeline is complex and time-sensitive.

Neither Moderna, Merck, nor any news outlet covering this story has disclosed projected pricing for intismeran autogene. Keytruda alone — pembrolizumab — already runs approximately $200,000 per year per patient, according to prior pharmaceutical pricing analyses. Add a custom-manufactured mRNA vaccine on top of that.

This will not be accessible to most Americans without serious insurance reform or government negotiation. That's a conversation worth having before this reaches approval.

The Results Speak for Themselves

Five years of data. A 49% reduction in recurrence risk. A 21-point survival gap. This is among the most substantive cancer trial results in recent years, built on technology that works, peer-reviewed in legitimate journals, and confirmed by both the companies involved and independent researchers.

The mRNA platform is a delivery mechanism for biological instructions — and right now those instructions are telling immune systems to kill cancer. Defunding this research because of COVID politics isn't skeptical. It's a policy choice with mortality consequences.